NXS 2.99% 32.5¢ next science limited

Next Science Limited is an emerging medical technology company,...

  1. 727 Posts.
    lightbulb Created with Sketch. 467
    • Next Science Limited is an emerging medical technology company, established in 2012, headquartered in Australia.
    • Next Science is commercialising its unique XbioTM technology platform through products that provide a non-toxictreatment for biofilm based infections.
    • Biofilms pose a far-reaching threat to humans, animals and the environment, representing 90% of all bacteria.
    • Bacteria protected by a biofilm can be 1,000x more resistant to antibiotics than free floating bacteria.
    • Over 70,000 patients have been treated with Xbio technology in the US market to date.
    • Next Science has 4 FDA cleared products currently in the US market to treat and manage surgical site infectionsand chronic wounds, and expects to have 8 products in market by the end of 2019 .
    • Distribution agreements with major multinationals validate the Company’s Xbio technology .
    • Next Science has a rapid growth trajectory with an extensive pipeline of products in both medical devices, OTCproducts and pharmaceutical applications
    • Unique, non-toxic platform technology with proven efficacy in eradicating biofilm andbacteria.
    • Addresses a clear unmet medical need and avoids creating antibacterial resistance
    • Commercial demand proven by early sales agreements with global industry leaders . Zimmer Biomet (global leader in joint replacements) for Bactisure surgical lavage (wash) 3M (a global leader in wound care) for BlastX wound gel
    • Multiple products targeting high value market segments with unmet needs
    • 8 products expected to be in market by end 2019
    • Extensive product pipeline across medical devices, OTC drugs and prescriptionpharmaceuticals
    • High margin and highly scalable production, with contract manufacturing in 4 countries
    • Broad international IP protection with 15 granted patents and 47 applications pending
    • Rapid sales growth through leveraging global distribution partners, launching new productsinto new markets, and via geographic expansion, with 8 products in market by end 2019
    • Next Science expects to benefit from multiple compounding growth drivers in 2019 and beyond:
    • Increased market penetration of existing products in the US market
    • Geographic expansion of sales outside the US- with entry to Australia and Europe expected in 2019
    • Development and commercialisation of new products and applications in human health
    • Next Science expects to have 8 products in market by end 2019, up from 2 in early 2018
    • Extension of Xbio technology into applications outside human health .
    • Manufacturing and production is highly scalable, using FDA or CE Mark audited contract manufacturers in theUSA, Europe, Australia and Mexico
    • Circa 500% revenue growth to A$20m in 2019 implied in management performance hurdles under the LTI plan

    It should do extremely well in short and medium term IMO and a potential multibagger for long term.

    It was very hard to get any stock in the IPO . Managed to get a tiny allocation in IPO .

    DYOR

    ALL IMO

    GLTAH
 
watchlist Created with Sketch. Add NXS (ASX) to my watchlist
(20min delay)
Last
32.5¢
Change
-0.010(2.99%)
Mkt cap ! $94.80M
Open High Low Value Volume
34.5¢ 34.5¢ 31.5¢ $32.36K 96.42K

Buyers (Bids)

No. Vol. Price($)
3 16254 32.0¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 29495 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
32.5¢
  Change
-0.010 ( 3.68 %)
Open High Low Volume
35.3¢ 35.3¢ 32.0¢ 61830
Last updated 15.59pm 28/03/2024 ?
NXS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.